NO may prompt calcium leakage in dystrophic muscle

Tidball, James G.; Villalta, S. Armando
March 2009
Nature Medicine;Mar2009, Vol. 15 Issue 3, p243
Academic Journal
The article presents a study which examines the new options for therapeutic interventions of Duchene muscular dystrophy (DMD). It states that the cause of DMD is the mutation in the gene that encodes dystrophin which is a low-prevalence, member-associated, cytoskeletal protein in the muscle. Bellinger and colleagues introduced a mechanism which may associate muscle inflammation with wasting and death of muscle in the standard model of DMD, mdx mouse.


Related Articles

  • In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G→A mutations in introns of the dystrophin gene. Habara, Y.; Takeshima, Y.; Awano, H.; Okizuka, Y.; Zhang, Z.; Saiki, K.; Yagi, M.; Matsuo, M. // Journal of Medical Genetics;Aug2009, Vol. 46 Issue 8, p7 

    Background: Splicing patterns are critical for assessing clinical phenotype of mutations in the dystrophin gene. However, it is still unclear how to predict alternative splicing pathways in such cases of splice-site mutation in the dystrophin gene. Objective: To identify elements determining...

  • Stem Cell Therapies to Treat Muscular Dystrophy. Meregalli, Mirella; Farini, Andrea; Parolini, Daniele; Maciotta, Simona; Torrente, Yvan // BioDrugs;2010, Vol. 24 Issue 4, p237 

    Muscular dystrophies are heritable, heterogeneous neuromuscular disorders and include Duchenne and Becker muscular dystrophies (DMD and BMD, respectively). DMD patients exhibit progressive muscle weakness and atrophy followed by exhaustion of muscular regenerative capacity, fibrosis, and...

  • Duchenne Muscular Dystrophy: From Diagnosis to Therapy. Falzarano, Maria Sofia; Scotton, Chiara; Passarelli, Chiara; Ferlini, Alessandra // Molecules;2015, Vol. 20 Issue 10, p18168 

    Duchenne muscular dystrophy (DMD) is an X-linked inherited neuromuscular disorder due to mutations in the dystrophin gene. It is characterized by progressive muscle weakness and wasting due to the absence of dystrophin protein that causes degeneration of skeletal and cardiac muscle. The...

  • Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic Diseases. Consalvi, Silvia; Saccone, Valentina; Giordani, Lorenzo; Minetti, Giulia; Mozzetta, Chiara; Puri, Pier Lorenzo // Molecular Medicine;May/Jun2011, Vol. 17 Issue 5/6, p457 

    Histone deacetylases inhibitors (HDACi) include a growing number of drugs that share the ability to inhibit the enzymatic activity of some or all the HDACs. Experimental and preclinical evidence indicates that these epigenetic drugs not only can be effective in the treatment of malignancies,...

  • Stem cells reverse muscular dystrophy. Mackenzie, Debora // New Scientist;11/18/2006, Vol. 192 Issue 2578, p12 

    The article presents information related to the treatment of Duchenne muscular dystrophy (DMD). Adult stem cells called mesangioblasts have helped dogs with muscular dystrophy to walk again. So, doctors hopes that a similar approach in humans can cure the disease in human. DMD is caused by...

  • Sizing up muscular dystrophy. Zammit, Peter S.; Partridge, Terence A. // Nature Medicine;Dec2002, Vol. 8 Issue 12, p1355 

    Reports on research which suggests that a treatment in a mouse model of Duchenne muscular dystrophy makes muscles larger and ameliorates symptoms of the disease. Reference to a study, published in the November 29, 2002 issue of 'Nature' magazine by Bogdanovich et al. which deals with the...

  • An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Smith, Bruce F.; Yue, Yongping; Woods, Philip R.; Kornegay, Joe N.; Shin, Jin-Hong; Williams, Regina R.; Duan, Dongsheng // Laboratory Investigation (00236837);Feb2011, Vol. 91 Issue 2, p216 

    Duchenne muscular dystrophy (DMD) is a dystrophin-deficient lethal muscle disease. To date, the catastrophic muscle wasting phenotype has only been seen in dystrophin-deficient humans and dogs. Although Duchenne-like symptoms have been observed in more than a dozen dog breeds, the mutation is...

  • Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse. Spurney, Christopher F.; Hee-Jae Cha; Sali, Arpana; Pandey, Gouri S.; Pistilli, Emidio; Guerron, Alfredo D.; Gordish-Dressman, Heather; Hoffman, Eric P.; Nagaraju, Kanneboyina // PLoS ONE;2010, Vol. 5 Issue 1, p1 

    Thymosin beta-4 (Tβ4) is a ubiquitous protein with many properties relating to cell proliferation and differentiation that promotes wound healing and modulates inflammatory mediators. We studied the effects of chronic administration of Tβ4 on the skeletal and cardiac muscle of dystrophin...

  • Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy. Lerario, Alberto; Cogiamanian, Filippo; Marchesi, Chiara; Belicchi, Marzia; Bresolin, Nereo; Porretti, Laura; Torrente, Yvan // BMC Musculoskeletal Disorders;2010, Vol. 11, p157 

    Background: The administration of rituximab (RTX) in vivo results in B-cell depletion, but evidence for multiple mechanisms of action have been reported. Surprisingly, B cell depletion produced a response in patients with polymyositis, which is characterized as a T cell-mediated autoimmune...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics